0.80
-0.0085(-1.05%)
Currency In USD
| Previous Close | 0.81 |
| Open | 0.81 |
| Day High | 0.85 |
| Day Low | 0.78 |
| 52-Week High | 17.19 |
| 52-Week Low | 0.61 |
| Volume | 669,349 |
| Average Volume | 929,008 |
| Market Cap | 129.3M |
| PE | -0.5 |
| EPS | -1.61 |
| Moving Average 50 Days | 0.75 |
| Moving Average 200 Days | 5.56 |
| Change | -0.01 |
If you invested $1000 in Neumora Therapeutics, Inc. Common Stock (NMRA) since IPO date, it would be worth $49.19 as of June 27, 2025 at a share price of $0.799. Whereas If you bought $1000 worth of Neumora Therapeutics, Inc. Common Stock (NMRA) shares 1 year ago, it would be worth $86.89 as of June 27, 2025 at a share price of $0.799.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
GlobeNewswire Inc.
Apr 28, 2025 11:00 AM GMT
WATERTOWN, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including two clinical-stage programs
Neumora Therapeutics to Present at Leerink Global Healthcare Conference
GlobeNewswire Inc.
Mar 04, 2025 1:30 PM GMT
WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today anno
Neumora Therapeutics Announces Leadership Transition
GlobeNewswire Inc.
Feb 13, 2025 12:00 PM GMT
Paul L. Berns, executive chair of Neumora Board of Directors, to serve as chief executive officer and chairman of the Board Joshua Pinto, Ph.D. to serve as president Bill Aurora, Pharm.D. to serve as chief operating and development officer; Michael M